Galapagos expands strategic alliance in metabolic disease with Merck & Co., Inc
Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
Cook Sues Endologix For Patent Infringement Over Aortic Aneurysm Endograft Technology
To keep up to date with news from this category use our ![]()
Cook Sues Endologix For Patent Infringement Over Aortic Aneurysm Endograft Technology
Bloomington, Ind., October 8, 2009 - In a move aimed at protecting its worldwide market-leading technology for endovascular repair of aortic aneurysms (EVAR), Cook Incorporated has filed a complaint with the U.S....
New Endovascular Graft for Thoracic Aortic Aneurysm Used in Australia for the First Time
Bloomington, Ind., October 8, 2009 -- For the first time in Australia, surgeons at the Royal Brisbane and Womens' Hospital have successfully treated a patient with an innovative new endovascular graft to repair a...
BioControl Medical cordially invites you to attend a presentation on: Chronic Vagus Nerve Stimulation in Patients with Heart Failure Potential Predictors of Success
October 7, 2009--Dr. Gaetano M. De Ferrari, director of the CCU at Policlinico S. Matteo and a member of the steeting committee of the Cardiofit Vagal Stimulation multicenter trial will present potential predictors of...
Unetixs Vascular Forms Strategic Alliance with Endothelix To Commercialize Significantly Improved Cardiovascular Diagnostic Technology
NORTH KINGSTOWN, R.I. (October 6, 2009) - Thanks to a strategic alliance announced today between Unetixs Vascular and Endothelix, early warning of an impending heart attack in asymptomatic patients soon will be possible...
CryoLife Receives Humanitarian Use Device Designation for SynerGraft(R) Processed Human Aortic Heart Valves
ATLANTA, Oct. 6 -- CryoLife, Inc., (NYSE: CRY) an implantable biological medical device and cardiovascular tissue processing company, today announced that it has received a Humanitarian Use Device (HUD) designation from...
Boston Scientific Announces FDA Clearance and U.S. and European Availability of WallFlex
NATICK, Mass., Oct. 6 -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its WallFlex(
MAQUET CARDIOVASCULAR RECEIVES FDA CLEARANCE FOR MEGA(TM), THE WORLD'S FIRST 8Fr. 50cc INTRA-AORTIC BALLOON CATHETER
Fairfield, NJ -October 01, 2009-- MAQUET Cardiovascular LLC, a leading provider of cardiovascular technologies, announced today at the Transcatheter Cardiovascular Therapeutics (TCT) convention in San Francisco, CA,...
Cepheid Receives FDA Clearance for Xpert
Sunnyvale, CA and Bedford, MA -- September 24, 2009 -- Cepheid (NASDAQ: CPHD) and Instrumentation Laboratory (IL) today announced that Cepheid has received clearance from the U.S. Food & Drug Administration (FDA) to...
Celladon's MYDICAR
San Diego, CA - September 23, 2009 - Celladon Corporation today announced that its SERCA2a programs for the treatment of patients with acute and chronic heart failure have been chosen by Windhover and an independent...
BioInvent updates on the progress of the Phase II trial of the long acting anticoagulant TB-402
Lund, Sweden - 23 September 2009 - BioInvent International AB (OMXS) announces that it has started recruitment of the third and final cohort of 100 patients for the Phase II trial of TB-402, a drug being developed for...
Abiomed Presents Results from USpella; First U.S. Registry Data Evaluating 181 Patients from 16 Centers with IRB Approval
DANVERS, Mass.--Sep. 22, 2009-- Abiomed Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies, today announced new clinical data from USpella, the first U.S. multicenter registry of Impella...
Cytokinetics Presents Phase IIa Clinical Trials Data Relating to Omecamtiv Mecarbil at the European Society of Cardiology Congress 2009
South San Francisco, CA - August 31, 2009--Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that data from two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable heart...
Integra NeuroSciences Features New MAYFIELD(R) Infinity XR2 Radiolucent Cranial Stabilization System At World Congress of Neurological Surgery
PLAINSBORO, N.J., August 31, 2009 -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) is featuring the MAYFIELD(R) Infinity XR2 Radiolucent Cranial Stabilization System at the XIV World Congress of Neurological...
Cytokinetics to Present Phase IIa Clinical Trials Data on Omecamtiv Mecarbil at the European Society of Cardiology Congress 2009
South San Francisco, CA - August 24, 2009--Cytokinetics, Incorporated (Nasdaq: CYTK) announced today that data relating to two Phase IIa clinical trials evaluating omecamtiv mecarbil (formerly CK-1827452), one in stable...
CathRx announces commencement of pilot trial for its irrigated ablation catheter
Sydney 17 June 2009: Cardiac catheter manufacturer CathRx Ltd (ASX: CXD) today announced it had commenced a human pilot trial of its first therapeutic catheter for use in both atrial flutter and atrial fibrillation...
BioControl Medical cordially invites you to attend a presentation on: Chronic Vagus Nerve Stimulation - A New Treatment Modality for Congestive Heart Failure
March 30, 2009--Dr. Gaetano M. De Ferrari, director of the CCU at Policlinico S. Matteo and a member of the steeting committee of the Cardiofit Vagal Stimulation multicenter trial will present the 6 month follow-up data...